Judith Balmañà

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer

Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

Breastfeeding after breast cancer in young <i>BRCA</i> carriers

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study

2274O Dissecting four decades of phase III randomised pharmacological interventions for primary cancer prevention to guide future developments: ESMO early detection and prevention task force

Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing

Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk

Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers

Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model

Germline TP53 pathogenic variants and breast cancer: A narrative review

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Data from Preclinical &lt;i&gt;In Vivo&lt;/i&gt; Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Abstract CT269: A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology